Melatonin for COVID-19
This trial will test if melatonin is safe and effective in treating adults suspected to have COVID-19.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2014 Phase 2 trial • 40 Patients • NCT01114373
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is this an innovative research endeavor?
"Since 2007, Melatonin has been the subject of 24 live studies spread across 9 countries and 12 cities. This journey began in 2007 with a 20 participant study backed by Eli Lilly & Co., culminating in formal drug approval for this medication."
What potential pitfalls are associated with Melatonin supplementation?
"Pre-existing data affirms the safety of Melatonin, thus it recieved a score of 2 on our scale. As this is only in Phase 2, there is no evidence yet to support efficacy."
Is enrollment for this experiment still available?
"Correct. According to the clinicaltrials.gov website, this investigation is currently recruiting participants and was initially posted on November 6th 2020 with recent changes made as of March 10th 2022. The overall goal is to recruit 30 patients from one particular site."
Are there any other empirical studies which have examined the efficacy of Melatonin?
"There are currently 24 medical trials actively researching the effects of Melatonin, with 4 trials in their concluding Phase 3. Although most studies take place around Houston, Texas, investigations into this medication span across 25 different sites."
How many individuals have been selected for participation in this experiment?
"Indeed, the clinicaltrials.gov portal confirms that this medical trial is currently recruiting patients. It was initially posted on November 6th 2020 and has been recently updated on March 10th 2022. A total of 30 participants are needed at one research centre for successful completion of this study."